Supported by

Tricuspid / Pulmonary valve

Find all the latest content on tricuspid or pulmonary valve published on this website.

Endovascular treatments for complications of the tricuspid or pulmonary valve, such as the treatment for tricuspid regurgitation (TR), are at an early stage of clinical development with many novel devices being introduced each year. This topic explores the different parameters of this emerging field with information on the latest research, emerging tools, devices and techniques, vascular access; the role of adjunctive pharmacotherapy; imaging techniques such as echocardiography as well as understanding bleeding risks or patient selection. Find out more…

Filtered By
Tricuspid / Pulmonary valve

527 results

How do we meet the needs of women with heart valve disease?

17 Nov 2025 – From PCR London Valves 2025

In this interview, Ellen Ross and Marta Sitges discuss a recent initiative from Global Heart Hub - a patient association - which examined the realities faced by women living with heart valve disease. They outline the gaps identified, the call to action that followed, and how...

How do we meet the needs of women with heart valve disease?

How are the new ESC/EACTS valvular guidelines going to impact my tricuspid programme?

17 Nov 2025 – From PCR London Valves 2025

While the PCR London Valves 2025 Course is underway, Francesco Maisano and Fabien Praz discuss how the latest ESC/EACTS valvular guidelines affect clinical practice. What’s changing in surgery? How do repair and replacement strategies differ under the new recommendations, and what’s the impact on transcatheter interventions?...

How are the 2025 ESC/EACTS valvular guidelines going to impact my tricuspid programme?

Tricuspid valve: PCR London Valves 2025 highlights

18 Nov 2025 – From PCR London Valves 2025

At PCR London Valves 2025, Course Directors Francesco Maisano and Nicolo Piazza highlight with Chris Allen the rapid evolution of tricuspid interventions. They emphasise advances in imaging and simulation, with dedicated labs offering practical multimodality training and hands-on experience. LIVE cases showcased both repair and replacement...

Tricuspid valve: PCR London Valves 2025 highlights

From pivotal trial to real-world impact: shaping TR treatment today with the EVOQUE system

16 Nov 2025 – From PCR London Valves 2025

Rebecca Hahn, Varius Dannenberg and Matti Adam discuss the updated ESC/EACTS guidelines for tricuspid regurgitation, which upgrade transcatheter tricuspid interventions to a IIa recommendation. Evidence from the TRILUMINATE and TRISCEND II trials shows improved quality of life and reduced heart failure hospitalisations, especially in patients with...

From pivotal trial to real-world impact: shaping TR treatment today with the EVOQUE system #PCRLV

Cracking the tricuspid code "the Bicaval revolution"

16 Nov 2025 – From PCR London Valves 2025

This session decodes the advancement of caval valve therapy with the TricValve system, offering novel solutions for tricuspid regurgitation and right heart failure. It incorporates insights from clinical trials, real-world cases, and guideline integration, detailing imaging techniques and strategies for complex patient management including rescue interventions.

Cracking the tricuspid code 'the Bicaval revolution'

From repair to replacement: a portfolio of options for your mitral and tricuspid regurgitation patients

16 Nov 2025 – From PCR London Valves 2025

This session explores a full spectrum of therapeutic options for mitral and tricuspid regurgitation, focusing on the PASCAL Precision system for targeted repair and the SAPIEN M3 transcatheter mitral valve replacement. Through beating heart simulators, case discussions, and clinical evidence, participants will understand the versatility and...

From repair to replacement: a portfolio of options for your mitral and tricuspid regurgitation patients

Late-Breaking Trials in transcatheter mitral, tricuspid and aortic interventions - Part 1

16 Nov 2025 – From PCR London Valves 2025

This session presents pivotal late-breaking trials in transcatheter mitral and aortic valve interventions. Explore one-year outcomes from the AltaValve early feasibility study featuring atrial fixation TMVR, interim results from the TARGET study assessing Cardiovalve for tricuspid regurgitation, five-year data on transapical TMVR, and outcomes of TAVI...

The Top Late-Breaking Trials - Part 1

Hotline - Mitral and tricuspid valvular interventions

16 Nov 2025 – From PCR London Valves 2025

This session delves into innovative mitral and tricuspid valvular interventions, highlighting outcomes with the PASCAL precision system and advances in combined MitraClip and TriClip repairs. It discusses predictors of heart failure hospitalization post-transcatheter tricuspid valve repair (TTVR), coronary CT-based pacemaker implantation prediction, and novel devices aimed...

Cutting-edge research in transcatheter tricuspid valve therapies

16 Nov 2025 – From PCR London Valves 2025

This session highlights cutting-edge research on tricuspid valve interventions, including the impact of inflow gradients on outcomes, global registry data on bicaval valve therapy, patient selection algorithms, and prognostic score validations for severe tricuspid regurgitation.

Cutting-edge research in transcatheter tricuspid valve therapies

New tricuspid valve devices

16 Nov 2025 – From PCR London Valves 2025

Examine new tricuspid valve devices and innovative procedural approaches, featuring cases of challenging anatomy with pacemaker lead repositioning, use of LuX-valve plus in massive regurgitation, position optimization in transjugular TTVR, and early clinical experiences from feasibility studies.